SPRAVATO (Intranasal Esketamine) is the new FDA approved treatment for Treatment-resistant Depression indicated for patients who have failed two adequate trials of other antidepressant medications.
To learn more about this treatment, please visit https://www.spravato.com.
Today’s most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine) in areas of the brain that affect mood.
SPRAVATO™ targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that SPRAVATO™ works is unknown. SPRAVATO™ is taken with a daily oral antidepressant.
The FDA has now approved the first drug that can relieve depression in hours instead of weeks. In a recent article titled “FDA Approves Esketamine Nasal Spray For Hard-To-Treat Depression,“ NPR stated:
“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” said Dr. Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, in a press release about the decision.
‘This is potentially a game-changer for millions of people,’ said Dr. Dennis Charney, Dean of the Icahn School of Medicine at Mount Sinai in New York. ‘It offers a lot of hope.’”
Spravato™ (esketamine) Recommended Treatment Protocols / Pricing:
Most insurance companies are now covering Spravato therapy; with a referral, our insurance coordinator can assist with your preauthorization. The recommended Spravato administration is typically twice a week for four weeks and then weekly or every other week thereafter.